RecruitingNCT07145918
Emraclidine safety and effects in adults with schizophrenia
About this title
Read the official source — NCT07145918This study evaluates the safety and effectiveness of Emraclidine for people with schizophrenia.
Medication studyAges 18–65United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Emraclidine for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Little Rock and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 4, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 268
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07145918
- Official title
Show the full official title
An Adaptive Two-part Randomized, Double Blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Emraclidine in Participants With Schizophrenia
Recruitment & locations
RecruitingLittle Rock · Glendale · Los Alamitos
4 more locations
- Gaithersburg
- Marlton
- Austin
- Richardson
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Emraclidine for people with schizophrenia.
Who is behind this study?
The study sponsor is AbbVie.
Does this study involve medication?
Yes. The study involves medication, including Emraclidine and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
